UK: Patenting Genetically Engineered Plants

Last Updated: 14 November 2002

The US perspective

It has been a long-standing practice in the US to allow the grant of utility patents for plants. The large biotech companies have sought to patent their genetically engineered ("GE") hybrids or lines in order to protect and exploit their investment in the technology. The outcome of the recent case of Pioneer1 has therefore provided reassurance to the agri-bio industry after the Supreme Court of the United States reaffirmed its earlier decision in Chakrabarty (supra) that utility patents are available for plants.

Pioneer Hi-Bred International ("Pioneer"), a subsidiary of DuPont, and the world’s largest producer of seed corn, had obtained 17 utility patents for its inbred and hybrid corn seed products under the US Code at 35 U.S.C. Section 101 (1994 ed) ("Section 101")2. Pioneer sells its patented hybrid seeds to merchants and growers under a limited licence, the terms of which only permit the production of grain and/or forage from that seed and prohibits re-sale and use of that seed for propagation, seed multiplication or the production or development of a new hybrid or variety.

J.E.M. Ag Supply (trading as "Farm Advantage") bought patented seed from Pioneer under the above licence and then resold it. Pioneer bought proceedings against Farm Advantage alleging patent infringement by Farm Advantage in selling or offering for sale the patented seed outside the scope of the licence agreement. In reply, Farm Advantage counterclaimed, arguing that Pioneer’s patents were invalid, because sexually reproducing plants were not patentable subject-matter within the scope of Section 101. In particular, Farm Advantage argued that the exclusive statutory means for the protection of plant life were set out in the Plant Patent Act 1930 ("PPA") and the Plant Variety Protection Act 1970 ("PVPA"): in effect, there was no residual discretion for the grant of plant patents under Section 101. Farm Advantage sought this restrictive ruling on the basis that the PVPA’s coverage is generally less extensive (for example, it allows exemptions for research and also for a farmer replanting farm saved seed) and also for the tactical reason that Pioneer had not obtained protection for the hybrid seed under the PVPA.

The District Court granted Pioneer summary judgment relying upon the broad construction of Section 101 in Diamond v. Chakrabarty3 in finding that Section 101 covered plant life and that in enacting the PPA and PVPA, Congress had not expressly or impliedly removed plants from Section 101’s ambit. In fact, it found that there was no conflict between the two statutes. The United States Court of Appeals for the Federal Circuit affirmed this decision. Farm Advantage then appealed to the Supreme Court.

The majority decision of the Supreme Court referred to its previous decision in Chakrabarty that: "Congress plainly contemplated that the patent laws would be given broad scope" by casting the provisions in broad terms to fulfil the constitutional and statutory goal of promoting the progress of science, and the associated social and economic benefits envisaged by Jefferson. The Supreme Court had in its earlier decision found nothing in the PPA or PVPA to limit the application of Section 101 to living things. Similarly, the fact that Congress could not have foreseen genetic engineering did not mean that the wide language of the provision could not embrace living things, without the need for further express authorisation from Congress.

The Supreme Court then went on to examine the relevant sections of the PPA and PVPA. It saw no reason why these various forms of protection for plants should not co-exist.

The PPA4 expressly allows protection for the asexual reproduction of a variety of plant (i.e. a clone produced, such as by grafting, budding or the like)5. Less stringent requirements are provided than for Section 101 utility patents, in that no plant patent can be declared invalid on the basis of non-compliance with the section, provided the description is made as complete as reasonably possible. The Supreme Court concluded its analysis by finding that nowhere did it state that plant patents are the exclusive means of granting intellectual property protection to plants.

In 1970, Congress expressly authorised limited patent-like protection for certain sexually reproduced plants under the PVPA6. Akin to UK The Plant Varieties Act 1997 (and driven by UPOV7) a plant variety certificate will be granted if the variety is new, distinct, uniform and stable (as opposed to the higher hurdles required for a utility patent of being useful and non-obvious). The PVPA is also subject to exemptions (such as research). A utility patent for a plant requires the plant to be described with sufficient specificity to enable others to make use of the invention after the patent expires, including a deposit of biological material which is available to the public, whereas the PVPA merely requires the deposit of seed in a public depository.

Accordingly, Justice Clarence Thomas found for the majority that neither the PPA nor the PVPA limited the scope of Section 101 to protect newly developed plant breeds. The Supreme Court saw no reason to upset the unbroken practice of the US PTO in having issued some 1800 utility patents for plants over the last 20 years.

The European perspective - the EPO Novartis Decision8

In 19959, the Technical Board of Appeal ("TBA") revoked the claims for individual plant varieties from a patent issued to Plant Genetics Systems BV of Belgium for the production of a herbicide-resistant plant on the grounds that the EU already had a system for protecting plant varieties (by granting Community plant breeders’ rights10) and the effect of Article 53(b)11 of the European Patent Convention ("EPC") was to prohibit the grant of patents on plant varieties. This decision appeared to conflict with the decision of the TBA in the earlier Oncomouse12 case where a literal interpretation of Article 53(b) allowed the TBA to uphold claims provided they did not claim protection for specific animal or plant varieties.

In the Novartis13 case, the Technical Board referred several questions to the EPO Enlarged Board of Appeal concerning claims in European Patent EP0448511, relating to certain plant varieties that were the result of a process to create transgenic plants by the insertion of the genes for lytic peptides and other hydrolytic enzymes in order to confer a pathogen resistant phenotype on the resultant organisms.

The main question considered by the Enlarged Board in case G01/98 was whether or not Article 53(b) EPC prohibited the protection of plant varieties through the patent system (and therefore whether the correct and only intellectual property right with which to protect plant varieties was the plant variety right).

The Enlarged Board commented that they thought it would be an odd anomaly, and a concept alien to patent law in general, if the application of the EPC were to prevent the patenting of specific embodiments of an invention (i.e. individual plant varieties), whilst allowing a broad claim to plants, the scope of which would include many such varieties. The Enlarged Board charted the development of Article 53(b) EPC through its drafting stages and concluded that its aim corresponded to that of Article 2(b) of the Strasbourg Convention14. The reason that the drafting of the two Articles differed was that the EPC draftsmen were working within in the constraints of the old UPOV ban on dual protection of plant varieties (which was abandoned in UPOV 1991), the desire to unify patent law throughout the EPC contracting states and the varying availability of plant variety right protection in the various EPC contracting states.

Significantly, between the time that the TBA in Novartis referred its questions to the Enlarged Board, and the Enlarged Board’s decision in G01/98, the EC adopted the EC Biotechnology Directive15. This Directive expressly allowed for the patenting of inventions concerning animal and plant life (Article 4) and the products of inventions concerning procedures, by which novel animals and plants (e.g. GE organisms) could be created (Articles 8 and 9). The Appellant in these proceedings (Novartis), naturally, submitted that the interpretation of the EPC (and, in particular, Article 53(b)) should be brought into line with this Directive.

The Enlarged Board ruled that a plant variety produced by genetic modification was a plant variety for the purposes of Article 53(b) and ultimately came to the conclusion that true purpose of Article 53(b) EPC was to define the partition between plant variety right protection and the patent system, i.e. a plant variety that qualified for plant variety right protection could not be patented, although if such a plant variety were an embodiment of a patentable invention, then the plant variety was also protected via the patent.

Therefore, the present position in Europe is that, a plant variety, or a group of plants that could be defined as a variety, cannot form the subject matter of a patent application no matter how they are generated, but can be patent protected if they are embodiments of inventions that independently qualify for patent protection.

Indeed, there is recognition of this overlap in Europe between patents and plant variety rights in Article 12 of the EC Biotechnology Directive (ante). That article provides for compulsory licensing of plant breeders’ rights and patent rights where the existence of one right hinders the acquisition or exploitation of the other right. Implementation of that objective is to be achieved in each Member State via a new regulatory framework for compulsory licences and cross-licences between holders of patents and plant breeders’ rights. In the UK, for example, implementation will be by means of the Patents and Plant Variety Rights Compulsory Licensing Regulations 2002, intended (at the time of writing) to take effect from 28 February 200216.

EU/US Dialogue

The joint EU/US Biotechnology Consultative Forum was launched at the Quelez Summit in May 2000 and delivered its report to the following EU/US Summit in Washington in December of that year17.

The report centred on suggestions for improvements in the regulation of the introduction of genetically modified crops. It also addressed the issue of how better to accommodate the concerns of the consumer, whilst satisfying the need to increase yields in general to feed a rising world population and alleviate the poverty suffered by millions in the world at present. The report recognised the concern that was felt in a number of quarters concerning the application of the patents system to the protection of plant varieties (both directly in the USA and indirectly in the EU as embodiments of patentable biotechnological inventions) and the potential conflict that exists between offering sufficient reward to the inventor or researcher by the grant of intellectual property rights and, what is seen by some as, the erosion of food security for the world’s poor.

The report made three recommendations and suggested a global dialogue be established concerning the creation of a new regime that could sufficiently reward inventors, whilst maintaining food security in poorer areas of the world. Those recommendations included:

  1. the protection of the farmer and research privileges;
  2. the rewarding of traditional or indigenous medical/agricultural knowledge utilised in any inventions; and
  3. the provision of incentives in developed countries for private companies to engage in research beneficial to developing countries.

The report is still under consideration by the European Commission and the recent Goteborg Conference suggested that areas are being identified in the report upon which are EU and US parties wish to work further.

Commercial, consumer and public perspectives

The large agri-bio companies face a dilemma in exploiting the advent of new GE plants in the global arena. Whilst the US permits agri-bio companies to file for (and obtain) patent protection for newly-developed hybrid or inbred plants or GE cell lines for introduction into conventionally-bred plant varieties, the position in Europe remains confused.

Similarly, whilst the US regulatory authorities have backed the wholescale introduction and commercialisation of GE crops, the regulatory authorities in the EU remain nervous in the face of considerable public opposition and consumer indifference as to the benefits which GE crops have to offer. In the UK, whilst the Government in partnership with industry (SCIMAC18) nears the end of the program for limited farm-scale plantings of certain GE crops, it is unclear whether the moratorium on the commercialisation of GE crops will be lifted. The "log-jam" of applications caught up in the EU regulatory approval process under Directive 90/220/EC and its successor, Directive 2001/18/EC for a Part C marketing consent has caused many agri-bio players to pause and think whether further investment in GE plants is warranted.

On the global stage, relations between large US agri-bio players and the developing world remain strained. In 1999, Larry Proctor obtained a US patent19 for an Enola bean described as: "a new field bean variety that produces distinctly coloured yellow-seed which remain relatively unchanged by season". It is reported that Mr. Proctor (through his seed company) then demanded royalties upon the import of all Mexican beans into the US. Such was the outrage by Mexican bean farmers, that the Mexican Government announced that it would contest the grant of the US patent. The International Center for Tropical Agriculture (CIAT) has sought re-examination of the patent on the basis that it lacks novelty and obviousness, the subject-matter being, it is claimed, merely derived from material of the native dry bean imported from Mexico20. CIAT holds the germplasm for over 27,000 samples of dry bean seed in its genebank as part of efforts to safeguard resources for the world’s farming community and to preserve biodiversity.

The developing nations regard such attempts to patent material, of crops they see as part of their cultural heritage, as "biopiracy"21. A similar outcry occurred last year in relation to the registration by US company RiceTech, Inc. of JASMATI as a US trade mark for a Texas-grown version of jasmine rice from Thailand. RiceTech, Inc. also obtained US patent protection in the form of a plant variety protection certificate under the PVPA. Although, the hybrid is in fact derived a cross of the American "della" and Italian "bertone" varieties, evidence has been produced that over half the US consumers bought Jasmati believing it to be a cross-breed of jasmine rice from Thailand and basmati rice from India/Pakistan. The Thai Government are reported as being extremely concerned at the potential damage to the Thai rice industry. Various legal moves have been made. Whilst this episode concerns the adoption of a name suggestive of a geographical indication, the depth of feeling is clear amongst developing countries which are heavily dependent upon farming communities for valuable export revenue.

In practice, the issue of whether GE plants should be patentable and, therefore, whether growers should be required to pay a technology licence fee for access to the new generation of crops is linked to the public’s perceived suspicion of GE plants and the technology in general. The other side of the equation is that without investigating the advances in food production, which biotechnology could bring, poverty and malnutrition can only increase as the global population swells. These issues should not be lost in the sensationalised media coverage of this area: there is a continued need for sensible, informed debate upon these issues drawing together the views of industry, consumers, environmental organisations and the governmental authorities.

What is clear is that there are still some large policy decisions for the EU Commission and Member States to address in order to clarify the position on patenting plant life (and, indeed, other forms of biotechnology). As with many things, this side of the transatlantic pond continues to be fringed with "weed" whilst the shore appears clearer in the US.

This article was first published in European Intellectual Property Review in June 2002.

1 J.E.M. AG Supply, Inc., dba Farm Advantage, Inc. et al v. Pioneer Hi-bred International, Inc., Supreme Court of the United States, 10 December 2001, No. 99-1996, reported at http://supct.law.cornell.edu/supct/html/99-1996.ZS.html.

2 Section 101 (inventions patentable) provides that: "Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title."

3 447 U.S. 303. In Diamond v. Chakrabarty, the Respondent filed a patent application relating to his invention of a human-made, genetically engineered bacterium capable of breaking down crude oil, a property not possessed by naturally occurring bacteria. The Patent Office refused protection (and that decision was upheld by the Board of Appeals) on the basis that living things are not patentable within Section 101. In 1980, the US Supreme Court held that a live, human-made micro-organism was patentable as it constituted a "manufacture" or "composition of matter" within the Statute. A broad construction of Section 101 was consistent with the enactment by Congress.

4 The PPA amended the general utility patent provision, Rev. Stat. §4886, to provide that: "Any person who has invented or discovered any new and useful art, machine, manufacture or composition of matter, or any new and useful improvements thereof, or who has invented or discovered and asexually reproduced any distinct and new variety of plant, other than a tuber-propagated plant, not known or used by others in this country, before his invention or discovery thereof, … may … obtain a patent therefor." Act of May 23, 1930, §1, 46 Stat. 376.

5 Further information can be found at http://www.uspto.gov/web/offices/pac/plant/.

6 "The breeder of any sexually reproduced or tuber propagated plant variety (other than fungi or bacteria) who has so reproduced the variety … ." 7 U.S.C. 2402(a).

7 The International Union for the Protection of New Varieties of Plants, Geneva 1991.

8 Decision G01/98 20.12.1999 (OJ EPO 3/2000 pp 111-171).

9 T 356/93 Plant cells/Plant Genetics Systems OJ EPO 1995, 354.

10 Council Regulation (EC) No. 2100/94 on Community plant variety rights (OJ 1.9.94 No L227/1).

11 Article 53(b) EPC reads: "European patents shall not be granted in respect of……plant or animal varieties or essentially biological processes for the production of plants or animals; this provision does not apply to microbiological processes or the products thereof."

12 T19/90 Oncomouse/Harvard, OJ EPO, 1990, 476.

13 T 1054/96 Transgenic Plant/Novartis, OJ EPO, 1998 511.

14 Strasbourg Patent Convention 1963

15 Directive 98/44/EC on the legal protection of biotechnological inventions.

16 On writing this article, the Working Draft of these regulations could be found at www.patent.gov.uk/about/consultations/written/220102s1.pdf.

17 The text of the report can be found at www.europa.eu.int/comm/external_relations/us/biotech/report.pdf.

18 The Supply Chain Initiative on Modified Agricultural Crops – a cross-industry grouping in the UK.

19 US Patent No. 5,894,079 which can be located on the US PTO’s website at www.uspto.gov.

20 For more information, please refer to the Rural Advancement Foundation International at www.rafi.org.

21 For further information, please see "Intellectual Property Rights and Food Security" by Michael Blakeney, [2000/2001] 3 BSLR 1

© Herbert Smith 2002

The content of this article does not constitute legal advice and should not be relied on as such. Specific advice should be sought about your specific circumstances.

For more information on this or other Herbert Smith publications, please email us.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
In association with
Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions